NASDAQ:OMCL Omnicell (OMCL) Stock Price, News & Analysis $45.29 +0.81 (+1.82%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$43.94▼$45.4250-Day Range$25.61▼$45.4352-Week Range$25.12▼$58.44Volume854,070 shsAverage Volume525,440 shsMarket Capitalization$2.08 billionP/E RatioN/ADividend YieldN/APrice Target$37.83 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Omnicell alerts: Email Address Omnicell MarketRank™ Stock AnalysisAnalyst RatingHold2.43 Rating ScoreUpside/Downside16.5% Downside$37.83 Price TargetShort InterestHealthy4.31% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.13Based on 3 Articles This WeekInsider TradingN/AProj. Earnings Growth18.75%From $0.64 to $0.76 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.50 out of 5 starsMedical Sector427th out of 910 stocksElectronic Computers Industry5th out of 6 stocks 2.2 Analyst's Opinion Consensus RatingOmnicell has received a consensus rating of Hold. The company's average rating score is 2.43, and is based on 3 buy ratings, 4 hold ratings, and no sell ratings.Amount of Analyst CoverageOmnicell has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Omnicell's stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted4.31% of the outstanding shares of Omnicell have been sold short.Short Interest Ratio / Days to CoverOmnicell has a short interest ratio ("days to cover") of 3.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Omnicell has recently decreased by 6.60%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldOmnicell does not currently pay a dividend.Dividend GrowthOmnicell does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for OMCL. Previous Next 2.3 News and Social Media Coverage News SentimentOmnicell has a news sentiment score of 1.13. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Omnicell this week, compared to 3 articles on an average week.Search InterestOnly 1 people have searched for OMCL on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Omnicell insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.64% of the stock of Omnicell is held by insiders.Percentage Held by Institutions97.70% of the stock of Omnicell is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Omnicell's insider trading history. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for Omnicell are expected to grow by 18.75% in the coming year, from $0.64 to $0.76 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Omnicell is -98.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Omnicell is -98.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Growth RatioOmnicell has a PEG Ratio of 49.29. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioOmnicell has a P/B Ratio of 1.73. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Omnicell's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the MarketsNASDAQ to crash 50%?During the 2020 Covid Crash he called a market reversal - eleven days before the S&P bottomed out... Now, he's saying there are four major cracks forming in the US economy...Click here to learn more >>> About Omnicell Stock (NASDAQ:OMCL)Omnicell, Inc., together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications. It also provides central pharmacy automation solutions; IV compounding robots; and inventory management software. In addition, the company provides single-dose automation solutions that fill and label a variety of patient-specific, single-dose medication blister packaging based on incoming prescriptions; fully automated and semi-automated filling equipment for institutional pharmacies to warrant automated packaging of medications; and medication blister card packaging and packaging supplies to enhance medication adherence in non-acute care settings. Further, it offers EnlivenHealth Patient Engagement, a web-based solutions. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was incorporated in 1992 and is headquartered in Fort Worth, Texas.Read More OMCL Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart OMCL Stock News HeadlinesSeptember 7 at 5:59 AM | markets.businessinsider.comOmnicell’s Strategic Rebranding and Market Outlook: A Hold RecommendationSeptember 4 at 2:11 AM | markets.businessinsider.comOmnicell’s Steady Growth and Hold Rating: A Cautious Outlook on Automation Services ExpansionSeptember 7, 2024 | Behind the Markets (Ad)NASDAQ to crash 50%?During the 2020 Covid Crash he called a market reversal - eleven days before the S&P bottomed out... Now, he's saying there are four major cracks forming in the US economy...August 29, 2024 | americanbankingnews.comOmnicell, Inc. (NASDAQ:OMCL) Receives $37.83 Consensus PT from AnalystsAugust 28, 2024 | markets.businessinsider.comPiper Sandler Remains a Buy on Omnicell (OMCL)August 28, 2024 | markets.businessinsider.comCraig-Hallum Remains a Buy on Omnicell (OMCL)August 28, 2024 | americanbankingnews.comOmnicell (NASDAQ:OMCL) PT Raised to $37.00 at JPMorgan Chase & Co.August 24, 2024 | au.finance.yahoo.comOmnicell, Inc. (OMCL) interactive stock chart – Yahoo FinanceSeptember 7, 2024 | Behind the Markets (Ad)NASDAQ to crash 50%?During the 2020 Covid Crash he called a market reversal - eleven days before the S&P bottomed out... Now, he's saying there are four major cracks forming in the US economy...August 22, 2024 | markets.businessinsider.comOmnicell (OMCL) Receives a Buy from Craig-HallumAugust 15, 2024 | finance.yahoo.comOmnicell to Present at the 2024 Wells Fargo Healthcare ConferenceAugust 4, 2024 | seekingalpha.comOmnicell, Inc. (OMCL) Q2 2024 Earnings Call TranscriptAugust 3, 2024 | msn.comBarclays Upgrades Omnicell (OMCL)August 2, 2024 | markets.businessinsider.comBuy Rating Affirmed for Omnicell Amid Strong Q2 Performance and Positive Market OutlookAugust 2, 2024 | msn.comOmnicell upgraded at Barclays after earnings-driven rallyAugust 2, 2024 | gurufocus.comQ2 2024 Omnicell Inc Earnings Call TranscriptAugust 1, 2024 | gurufocus.comOmnicell Inc (OMCL) Q2 2024 Earnings: EPS of $0.08, Revenue of $277 Million, Exceeds EstimatesJuly 25, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Omnicell (OMCL) and Argenx Se (ARGX)See More Headlines Receive OMCL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Omnicell and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/01/2024Today9/07/2024Next Earnings (Estimated)11/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Electronic computers Sub-IndustryHealth Care Technology Current SymbolNASDAQ:OMCL CUSIP68213N10 CIK926326 Webwww.omnicell.com Phone(877) 415-9990Fax847-596-3402Employees3,650Year Founded1992Price Target and Rating Average Stock Price Target$37.83 High Stock Price Target$44.00 Low Stock Price Target$30.00 Potential Upside/Downside-16.5%Consensus RatingHold Rating Score (0-4)2.43 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($0.46) Trailing P/E RatioN/A Forward P/E Ratio70.77 P/E Growth49.29Net Income$-20,370,000.00 Net Margins-1.92% Pretax Margin-1.92% Return on Equity2.52% Return on Assets1.33% Debt Debt-to-Equity Ratio0.47 Current Ratio2.45 Quick Ratio2.22 Sales & Book Value Annual Sales$1.15 billion Price / Sales1.82 Cash Flow$3.20 per share Price / Cash Flow14.15 Book Value$26.15 per share Price / Book1.73Miscellaneous Outstanding Shares45,990,000Free Float44,711,000Market Cap$2.08 billion OptionableOptionable Beta0.83 Social Links The Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesMr. Randall A. Lipps (Age 67)Founder, Executive Chairman, President & CEO Comp: $1.85MMr. Nchacha E. Etta (Age 52)Executive VP & CFO Comp: $480.21kMr. Corey J. Manley (Age 46)Executive VP, Chief Legal & Administrative Officer and Corporate Secretary Comp: $715.33kMs. Minoo MortazaviSenior Vice President of Global OperationsMr. Brian H. Nutt (Age 54)VP, Chief Accounting Officer & Corporate Controller Mr. Giri ChodavarapuSenior VP & Chief Information OfficerMs. Kathleen NemethSenior Vice President of Investor RelationsMr. Maximo RochaSenior VP & Chief People OfficerMr. Joseph Brian Spears (Age 64)Executive Adviser Ms. Sara DalmassoSenior VP & GM of InternationalMore ExecutivesKey CompetitorsFitbitNYSE:FITVeradigmNASDAQ:MDRXHealthStreamNASDAQ:HSTMHuamiNYSE:HMICortexymeNASDAQ:CRTXView All CompetitorsInstitutional OwnershipAlgert Global LLCBought 4,617 shares on 8/16/2024Ownership: 0.113%Susquehanna International Group LLPBought 13,000 shares on 8/16/2024Ownership: 0.000%AQR Capital Management LLCBought 4,572 shares on 8/15/2024Ownership: 0.107%Deerfield Management Company L.P. Series CBought 22,174 shares on 8/15/2024Ownership: 0.069%The Manufacturers Life Insurance Company Bought 1,360 shares on 8/15/2024Ownership: 0.051%View All Institutional Transactions OMCL Stock Analysis - Frequently Asked Questions How have OMCL shares performed this year? Omnicell's stock was trading at $37.63 at the beginning of 2024. Since then, OMCL stock has increased by 20.4% and is now trading at $45.29. View the best growth stocks for 2024 here. How were Omnicell's earnings last quarter? Omnicell, Inc. (NASDAQ:OMCL) announced its quarterly earnings results on Thursday, August, 1st. The company reported $0.51 earnings per share for the quarter, topping analysts' consensus estimates of $0.14 by $0.37. The company's quarterly revenue was down 7.4% on a year-over-year basis. What is Randall A. Lipps' approval rating as Omnicell's CEO? 150 employees have rated Omnicell Chief Executive Officer Randall A. Lipps on Glassdoor.com. Randall A. Lipps has an approval rating of 68% among the company's employees. Does Omnicell have any subsidiaries? The following companies are subsidiaries of Omnicell: MarkeTouch Media LLC, ReCept Pharmacy, FDS Amplicare, 340B Link Business, InPharmics, Ateb Inc., Aesynt, and others. Who are Omnicell's major shareholders? Top institutional shareholders of Omnicell include Pacer Advisors Inc. (4.51%), Dimensional Fund Advisors LP (2.57%), Bank of New York Mellon Corp (2.37%) and Federated Hermes Inc. (2.16%). Insiders that own company stock include Randall A Lipps, Peter J Kuipers, Scott Peter Seidelmann, Joanne B Bauer, Christine Marie Mellon, Joseph Brian Spears and Dan S Johnston. View institutional ownership trends. How do I buy shares of Omnicell? Shares of OMCL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Omnicell own? Based on aggregate information from My MarketBeat watchlists, some other companies that Omnicell investors own include AT&T (T), AbbVie (ABBV), Johnson & Johnson (JNJ), Gilead Sciences (GILD), Adobe (ADBE), Micron Technology (MU) and NVIDIA (NVDA). This page (NASDAQ:OMCL) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredThese 5 stocks could soar after November 4thHow to Trade this Crazy Election Year? Simple – Just Focus on These 5 stocks… Now available – a free report...StockEarnings | SponsoredKamala’s Dirty Election Move… RevealedAccording to former advisor to the CIA, the Pentagon and the White House Jim Rickards… Kamala and her puppe...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Omnicell, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Omnicell With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.